8) TMT/HFV
Abstract
Transformational Medical Technologies (TMT) Program/Hemorrhagic Fever Virus (HFV) - TMT will advance broad-spectrum or platform-based MCM candidates against viruses such as Ebola, Marburg and Junin through the Technology Development phase. TMT will complete preclinical evaluation to achieve IND status (as necessary) and initiate and complete Phase I clinical studies where drug candidates are introduced into humans and early evidence is gathered on drug safety. TMT will conclude the TD Phase by completing all activities associated with Phase 1 clinical studies. The results of the TD Phase clinical studies will support a Milestone B decision to continue toward a New Drug Application (NDA) and FDA approval/licensure.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2012
- Source ID
- 9d1441973174313fafe64c669cc5de97